NASDAQ · ABBV
Healthcare · Drug Manufacturers - General
$260.21
Down-$4.05 (-1.56%)
Updated Sep 4, 2026, 5:56 PM
SID Score
7.4/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ABBV closed at $260.21 after 21 trading sessions, up 6.70% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 3, 2026 | $264.00 | $264.25 | $257.14 | $260.21 | 2.88M |
| Sep 2, 2026 | $262.70 | $262.97 | $257.70 | $261.72 | 4.23M |
| Sep 1, 2026 | $260.99 | $262.265 | $257.79 | $259.99 | 3.87M |
| Aug 31, 2026 | $254.17 | $258.24 | $252.33 | $256.42 | 4.32M |
| Aug 28, 2026 | $258.67 | $259.00 | $255.0797 | $255.48 | 3.22M |
| Aug 27, 2026 | $260.81 | $262.4977 | $257.25 | $258.15 | 4.76M |
| Aug 26, 2026 | $264.60 | $265.00 | $260.31 | $262.90 | 3.31M |
| Aug 25, 2026 | $264.50 | $266.905 | $263.025 | $265.79 | 3.67M |
| Aug 24, 2026 | $263.99 | $266.0395 | $262.07 | $264.52 | 3.88M |
| Aug 21, 2026 | $260.70 | $266.84 | $260.101 | $264.96 | 5.16M |
| Aug 20, 2026 | $265.69 | $265.93 | $260.4812 | $261.83 | 5.23M |
| Aug 19, 2026 | $261.51 | $266.965 | $259.55 | $265.97 | 5.54M |
| Aug 18, 2026 | $253.93 | $259.18 | $252.41 | $258.92 | 5.01M |
| Aug 17, 2026 | $249.49 | $251.49 | $248.31 | $250.33 | 4.65M |
| Aug 14, 2026 | $250.60 | $250.61 | $247.68 | $249.46 | 4.2M |
| Aug 13, 2026 | $252.94 | $255.295 | $249.35 | $250.82 | 4.37M |
| Aug 12, 2026 | $245.98 | $250.09 | $245.52 | $248.76 | 3.78M |
| Aug 11, 2026 | $248.14 | $250.765 | $247.18 | $250.09 | 4.49M |
| Aug 10, 2026 | $245.65 | $248.01 | $244.03 | $247.97 | 4.21M |
| Aug 7, 2026 | $243.62 | $246.76 | $241.95 | $246.04 | 4.93M |
| Aug 6, 2026 | $249.04 | $249.95 | $241.20 | $243.87 | 4.57M |
The latest Smart Investors Daily articles mentioning ABBV.
ABBV research
Company profile and research snapshot.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | Piper Sandler | Overweight | — |
| Aug 17, 2026 | Wells Fargo | Overweight | — |
| Aug 13, 2026 | Wolfe Research | Outperform | — |
| Aug 11, 2026 | BNP Paribas | Neutral | — |
| Aug 10, 2026 | Evercore ISI Group | Outperform | — |
Generated Sep 4, 2026, 3:00 PM
AbbVie shares declined 1.25% today despite a stream of positive clinical and operational news, suggesting investors are digesting near-term earnings guidance that fell slightly short of consensus expectations while balancing encouraging long-term pipeline developments. The company's successful Phase 3 data for its multiple myeloma drug etentamig and completed Apogee acquisition are overshadowed by the earnings dilution these moves will create in the near term.
Bottom line: AbbVie is experiencing a modest pullback as the market processes mixed signals—compelling pipeline progress in oncology offset by cautious near-term guidance and dilutive acquisition economics. Investors should view this dip as an opportunity to accumulate ahead of key upcoming presentations, though patience will be required given the company's 2032 timeline for Apogee accretion and its defensive market positioning.
Yahoo · Sep 4, 2026
AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the patent reckoning already underway.
Yahoo · Sep 4, 2026
Owning two or three dividend ETFs feels like extra protection, but it can quietly leave retirees paying multiple expense ratios for a nearly identical stack of stocks. Here is how the five most popular options actually differ, and why the wrong combination costs more than most people realize.
Yahoo · Sep 4, 2026
AbbVie (NYSE: ABBV) reported positive Phase 3 CERVINO trial results for etentamig, an investigational BCMA x CD3 bispecific T-cell engager in relapsed or refractory multiple myeloma. The study found etentamig outperformed standard therapies with strong efficacy and a manageable safety profile in a difficult-to-treat patient group. The data may support a future regulatory submission and potential market entry for etentamig in the BCMA-targeted therapies space. Consider reviewing other...
SeekingAlpha · Sep 4, 2026
AbbVie is supported by robust fundamentals, a strong immunology portfolio, and attractive valuation metrics. Find out why ABBV stock is a Buy.
Interpretive context generated from the platform’s current data sources.
AbbVie Inc. shares traded at $260.30, reflecting a single-session decline of 1.32% per SID market data. Despite the daily pullback, the stock has demonstrated consistent upward momentum across multiple timeframes, gaining 7.35% over the past month, 20.54% over three months, and 15.76% over the trailing twelve months. The stock currently trades above both key moving averages, with the 50-day moving average at $253.71 and the 200-day moving average at $227.57, indicating sustained bullish positioning according to SID market data. The 14-day RSI reads 62.6, suggesting moderate momentum without entering overbought territory. AbbVie's beta of 0.334 reflects significantly lower volatility relative to the broader market, consistent with the defensive characteristics of the healthcare sector. Average daily trading volume stands at approximately 6.4 million shares, supporting a market capitalization of roughly $410 billion, according to Massive/Polygon data.
AbbVie Inc. currently trades at a trailing price-to-earnings ratio of 97.75, a notably elevated figure that reflects the impact of significant non-cash charges and amortization expenses tied to the company's acquisition-heavy growth strategy, per SID market data. The PEG ratio stands at 1.25, suggesting the earnings multiple is more reasonable when adjusted for expected growth, according to SEC filings. The company's price-to-book ratio is negative at -126.33, a result of accumulated goodwill write-downs and substantial share repurchase activity that have pushed book value into negative territory. AbbVie maintains a dividend yield of approximately 2.87%, positioning it as a meaningful income-generating holding within the healthcare sector. The company's $410 billion market capitalization reflects investor confidence in its forward earnings power despite the optically high trailing PE, as the pharmaceutical giant continues transitioning its revenue base beyond legacy Humira sales toward newer immunology and oncology franchises.
AbbVie Inc. registers a composite smart money score of 54, signaling a neutral overall stance among sophisticated market participants, per SID market data. The institutional component scores a perfect 25 out of 25, indicating exceptionally strong conviction from large fund managers and asset allocators. The insider trading component also scores highly at 18 out of 25, supported by two insider transactions recorded over the past 90 days — both of which were purchases with zero insider sales reported during the period, according to SEC Form 4 filings. This buy-only insider activity suggests management confidence in the company's near-term trajectory. In contrast, the dark pool activity score is relatively muted at 9.8 out of 25, indicating lower levels of off-exchange block trading interest. Congressional trading activity is minimal, scoring just 0.8 out of 25 per 13F institutional filings. The divergence between strong institutional and insider signals against subdued dark pool and congressional activity creates a mixed but net-positive smart money profile for AbbVie.
AbbVie Inc. has delivered a mixed recent earnings record, per company earnings reports. In the most recent reported quarter, the company posted earnings per share of $3.65 against an analyst consensus estimate of $3.77, resulting in a miss of $0.12. The prior quarter showed a narrower shortfall, with actual EPS of $2.65 versus the $2.66 estimate, a negative surprise of just $0.01. Earlier, AbbVie reported EPS of $2.71 against a $2.66 estimate, delivering a positive surprise of $0.05. The upcoming quarterly report carries a consensus estimate of $3.01 per share, according to analyst estimates. The sequential earnings trajectory from $2.71 to $2.65 to $3.65 reflects meaningful quarter-over-quarter variability, though the overall trend remains upward. Analysts will closely monitor the cadence of newer product revenue contributions, particularly from Skyrizi and Rinvoq, as these franchises increasingly anchor the company's growth narrative.
Wall Street consensus on AbbVie Inc. leans constructively positive based on recent analyst activity, per SID consensus data. Piper Sandler reiterated its Overweight rating on August 20, while Wells Fargo maintained its own Overweight rating on August 17, reflecting continued bullish conviction among sell-side coverage, according to Wall Street analyst reports. Notably, Wolfe Research upgraded ABBV to Outperform from Peer Perform on August 13, representing the most significant rating change in the recent cycle and signaling improved conviction in the company's growth outlook. BNP Paribas maintained a Neutral stance on August 11, providing a more cautious counterpoint within the coverage universe. Evercore ISI Group reiterated its Outperform rating on August 10. Of the five most recent analyst actions, four carry bullish designations — either Overweight or Outperform — while only one maintains a Neutral position. The Wolfe Research upgrade is particularly noteworthy as it reflects a directional shift rather than a simple reiteration of existing sentiment.
The latest Smart Investors Daily articles mentioning ABBV.
